OMNIlife science announced the first clinical use of novel robotic tissue balancing with the OMNIBotics® robotic-assisted total knee replacement platform, occurring in Australia.
The OMNIBotics system, based on proprietary ART™ software (APEX Robotic Technology), has been used globally in >13,000 procedures to date, supporting patient-specific procedures and eliminating the need for pre-op CT scans or x-rays.
OMNIBotics has approval under the CE Mark; a 510(k) has been submitted to FDA for U.S. clearance.
OMNIlife science announced the first clinical use of novel robotic tissue balancing with the OMNIBotics® robotic-assisted total knee replacement platform, occurring in Australia.
The OMNIBotics system, based on proprietary ART™ software (APEX Robotic Technology), has been used globally in >13,000 procedures to date, supporting...
OMNIlife science announced the first clinical use of novel robotic tissue balancing with the OMNIBotics® robotic-assisted total knee replacement platform, occurring in Australia.
The OMNIBotics system, based on proprietary ART™ software (APEX Robotic Technology), has been used globally in >13,000 procedures to date, supporting patient-specific procedures and eliminating the need for pre-op CT scans or x-rays.
OMNIBotics has approval under the CE Mark; a 510(k) has been submitted to FDA for U.S. clearance.
Copy to clipboard 
